Cargando…

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion

SIMPLE SUMMARY: We assessed the efficacy and safety of low-dose apatinib monotherapy as a third-line treatment in patients with metastatic colorectal cancer. The ORR and DCR were 4.0% (2/50) and 70% (35/50), and the median PFS and OS were 4.7 months and 10.1 months, which demonstrated comparable sur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lingying, Yu, Qiang, Gao, Chunyi, Xiang, Jingzhou, Zheng, Bowen, Feng, Yujie, Li, Runyang, Zhang, Wenqing, Hong, Xiaoting, Zhan, Yan-yan, Xiao, Li, Hu, Tianhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139438/ https://www.ncbi.nlm.nih.gov/pubmed/35626097 http://dx.doi.org/10.3390/cancers14102492

Ejemplares similares

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma
por: Cui, Lixuan, et al.
Publicado: (2021)

Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study
por: Xiao, Yan, et al.
Publicado: (2019)

Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies
por: Li, Haosheng, et al.
Publicado: (2022)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
por: Jin, Jun, et al.
Publicado: (2019)

Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
por: Wang, Fen, et al.
Publicado: (2020)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Apatinib inhibits tumor growth and angiogenesis in PNET models
por: Wu, Shan, et al.
Publicado: (2018)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Xu, Jianping, et al.
Publicado: (2020)

Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells
por: Li, YanWei, et al.
Publicado: (2022)

Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
por: Jia, Wenqing, et al.
Publicado: (2022)

Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma
por: Li, Xiaofen, et al.
Publicado: (2018)

Clinical observation of apatinib-related hypothyroidism in patients with advanced malignancies
por: Xiao, Junjuan, et al.
Publicado: (2020)

Apatinib for molecular targeted therapy in tumor
por: Zhang, Haijun
Publicado: (2015)

Apatinib monotherapy for advanced non‐small cell lung cancer after the failure of chemotherapy or other targeted therapy
por: Liu, Zui, et al.
Publicado: (2018)

Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017)

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
por: Cui, Qingli, et al.
Publicado: (2022)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis
por: Huang, Xuchen, et al.
Publicado: (2022)

Effective apatinib treatment of pleomorphic liposarcoma: A case report
por: Yan, Peng, et al.
Publicado: (2017)

Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients
por: Liu, Mingtao, et al.
Publicado: (2020)

Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report
por: Li, Ting, et al.
Publicado: (2019)

Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study
por: Geng, Qian, et al.
Publicado: (2020)

Apatinib treatment is effective for metastatic malignant phyllodes tumors of the breast: a case report
por: Wang, Xiaolu, et al.
Publicado: (2021)

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
por: Lin, Hao, et al.
Publicado: (2023)

Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC)
por: Shi, Liang, et al.
Publicado: (2022)

Application of apatinib after multifaceted therapies for metastatic breast cancer
por: Wang, Jue, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Fatal hemoptysis in patients with advanced esophageal cancer treated with apatinib
por: Wang, Wei, et al.
Publicado: (2018)

Advanced alveolar soft part sarcoma responds to apatinib
por: Zhou, Yong, et al.
Publicado: (2017)

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
por: Pan, Zhongmian, et al.
Publicado: (2023)

Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2022)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review
por: Zhang, Di, et al.
Publicado: (2019)

Effects of Apatinib Mesylate Monotherapy on the Incidence of Adverse Reactions and Immune Function in Patients with Breast Cancer after Radical Mastectomy
por: Lin, Sen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q76ns7dmn0813bo98oi823oeqq